The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa
Abstract
RATIONALE: The dual challenges to tuberculosis (TB) control of HIV infection and multidrug resistance are particularly pressing in South Africa. Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings. OBJECTIVES: To assess the performance and feasibility of implementation of a commercially available molecular line-probe assay for rapid detection of rifampicin and isoniazid resistance. METHODS: We performed the assay directly on 536 consecutive smear-positive sputum specimens from patients at increased risk of multidrug-resistant (MDR) TB in a busy routine diagnostic laboratory in Cape Town, South Africa. Results were compared with conventional liquid culture and drug susceptibility testing on solid medium. MEASUREMENTS AND MAIN RESULTS: Overall, 97% of smear-positive specimens gave interpretable results within 1-2 days using the molecular assay. Sensitivity, specificity, and positive and negative predictive values were 98.9, 99.4, 97.9, and 99.7%, respectively, for detection of rifampicin resistance; 94.2, 99.7, 99.1, and 97.9%, respectively, for detection of isoniazid resistance; and 98.8, 100, 100, and 99.7%, respectively, for detection of multidrug resistance compared with conventional results. The assay also performed well on specimens that were contaminated on conventional culture and on smear-negative, culture-positive specimens. CONCLUSIONS: This molecular assay is a highly accurate screening tool for MDR TB, which achieves a substantial reduction in diagnostic delay. With overall performance characteristics that are superior to conventional culture and drug susceptibility testing and the possibility for high throughput with substantial cost savings, molecular testing has the potential to revolutionize MDR TB diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
(2006) · PsycEXTRA Dataset · doi:10.1037/e566482006-002 · Cited by 513
Hillemann, D., Rüsch-Gerdes, S., & Richter, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00521-07 · Cited by 345
Management of tuberculosis : a guide for low income countries
Enarson, D. A., Rieder, H. L., Arnadottir, T., & Trébucq, A. (2000) · Cited by 200
Kiepiela, P., Bishop, K. S., Smith, A. N., Roux, L., & York, D. F. (2000) · Tubercle and Lung Disease · doi:10.1054/tuld.1999.0231 · Cited by 139
Miotto, P., Piana, F., Penati, V., Canducci, F., Migliori, G. B., & Cirillo, D. M. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00083-06 · Cited by 113
Baker, L. V., Brown, T., Maxwell, O., Gibson, A. L., Fang, Z., Yates, M. D., & Drobniewski, F. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1455-1464.2005 · Cited by 78
Yagui, M., Perales, M. T., Asencios, L., Vergara, L. F., Suárez, C., Yale, G., Salazar, C., Saavedra, M., Shin, S. S., Ferrousier, O., et al. (2006) · PubMed · Cited by 75
Notice to Readers: Revised Definition of Extensively Drug-Resistant Tuberculosis
(2006) · JAMA · doi:10.1001/jama.296.23.2792-a · Cited by 42
Cited by
Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Transforming clinical microbiology with bacterial genome sequencing
Didelot, X., Bowden, R., Wilson, D. J., Peto, T. E. A., & Crook, D. W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3226 · Cited by 799
Karim, S. S. A., Churchyard, G. J., Karim, Q. A., & Lawn, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60916-8 · Cited by 545
Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities
Parsons, L. M., Somoskövi, Á., Gutierrez, C., Lee, E., Paramasivan, C. N., Abimiku, A., Spector, S., Roscigno, G., & Nkengasong, J. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-10 · Cited by 540
Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Metadata
- Authors
- Barnard, M., Albert, H., Coetzee, G., O'Brien, R., & Bosman, M. E.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-01
- Volume
- 177
- Issue
- 7
- Pages
- 787-792
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2168848141
- Cited by
- 391
- References
- 10
- FWCI
- 31.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa. https://app.cochat.ai/papers/10.1164/rccm.200709-1436oc
- The paper
- Barnard, M., Albert, H., Coetzee, G., O'Brien, R., & Bosman, M. E. (2008). Rapid Molecular Screening for Multidrug-Resistant Tuberculosis in a High-Volume Public Health Laboratory in South Africa. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200709-1436oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.